62 participants with constipation predominant IBS (IBS-C) and 60 participants with diarrhoea predominant IBS (IBS-D) were dosed with EBX-102-02 or matching placebo and followed up for six weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback